(VIANEWS) – CleanSpark (CLSK), Chart Industries (GTLS), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. CleanSpark (CLSK)
117.4% sales growth and 7.14% return on equity
CleanSpark, Inc. engages in bitcoin mining operations. It develops sustainable infrastructure for Bitcoin, a tool for financial independence and inclusion. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.
Earnings Per Share
As for profitability, CleanSpark has a trailing twelve months EPS of $0.13.
PE Ratio
CleanSpark has a trailing twelve months price to earnings ratio of 125.71. Meaning, the purchaser of the share is investing $125.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.14%.
Yearly Top and Bottom Value
CleanSpark’s stock is valued at $16.34 at 11:22 EST, way under its 52-week high of $24.72 and way above its 52-week low of $3.38.
2. Chart Industries (GTLS)
18.2% sales growth and 3.2% return on equity
Chart Industries, Inc. manufactures and sells engineered cryogenic equipment for the industrial gas and clean energy markets in the United States and internationally. The company operates in four segments: Cryo Tank Solutions, Heat Transfer Systems, Specialty Products, and Repair, Service & Leasing. It provides bulk and packaged gas cryogenic solutions for the storage, distribution, vaporization, and application of industrial gases; cryogenic trailers, ISO containers, bulk storage tanks, loading facilities, and regasification equipment for delivering liquefied natural gas (LNG) into virtual pipeline applications; and large vacuum insulated storage tanks as equipment for purchasers of standard liquefaction plants. The company also offers natural gas processing solutions; process technology, liquefaction capabilities, and critical equipment for the LNG, include small to mid-scale facilities, floating LNG applications, and large base-load export facilities; brazed aluminum heat exchangers, Core-in-Kettle heat exchangers, cold boxes, air cooled heat exchangers, pressure vessels, and pipe works; and air cooled heat exchangers and axial cooling fans for the HVAC, power, and refining applications. In addition, it provides highly engineered equipment that is used in specialty end-market applications for hydrogen, LNG, biofuels, CO2 Capture, food and beverage, aerospace, lasers, cannabis, and water treatment; and cryogenic components, include vacuum insulated pipes, specialty liquid nitrogen, end-use equipment, and cryogenic flow meters. Further, it provides extended warranties, plant start-up, parts, 24/7 support, monitoring and process optimization, repairing, maintenance, and upgrading services; plant services on equipment; and service locations that undertake installation, service, repair, maintenance, and refurbishment of cryogenic products, as well as equipment leasing solutions. Chart Industries, Inc. was founded in 1859 and is headquartered in Ball Ground, Georgia.
Earnings Per Share
As for profitability, Chart Industries has a trailing twelve months EPS of $1.12.
PE Ratio
Chart Industries has a trailing twelve months price to earnings ratio of 125.42. Meaning, the purchaser of the share is investing $125.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.2%.
3. United Therapeutics Corporation (UTHR)
15.9% sales growth and 20.08% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.11.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 15.11. Meaning, the purchaser of the share is investing $15.11 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
4. Medpace Holdings (MEDP)
12.9% sales growth and 61.35% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $9.83.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 41.27. Meaning, the purchaser of the share is investing $41.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 61.35%.
Sales Growth
Medpace Holdings’s sales growth is 14.7% for the present quarter and 12.9% for the next.
Yearly Top and Bottom Value
Medpace Holdings’s stock is valued at $405.68 at 11:22 EST, below its 52-week high of $421.00 and way above its 52-week low of $214.32.
Volume
Today’s last reported volume for Medpace Holdings is 135403 which is 36.04% below its average volume of 211712.
Previous days news about Medpace Holdings(MEDP)
- According to Zacks on Tuesday, 25 June, "While Hims & Hers and The Joint currently sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy). "
5. First Guaranty Bancshares (FGBI)
12.7% sales growth and 3.37% return on equity
First Guaranty Bancshares, Inc. operates as the holding company for First Guaranty Bank that provides commercial banking services in Louisiana and Texas. It offers various deposit products, including personal and business checking, savings, money market, and demand accounts, as well as time deposits to consumers, small businesses, and municipalities. The company also provides loans, such as non-farm non-residential loans secured by real estate, commercial and industrial loans, one- to four-family residential loans, multifamily loans, construction and land development loans, agricultural loans, farmland loans, and consumer and other loans to small to medium-sized businesses and professionals, and individuals. In addition, it offers a range of consumer services, including personal and commercial credit cards, remote deposit capture, safe deposit boxes, official checks, online and mobile banking, automated teller machines, and online bill pay; provides additional solutions, such as merchant services, remote deposit capture, and lockbox services to business customers; and invests a portion of its assets in securities issued by the United States Government and its agencies, state and municipal obligations, corporate debt securities, mutual funds, and equity securities, as well as invests in mortgage-backed securities primarily issued or guaranteed by United States Government agencies or enterprises. The company operates through 34 banking facilities primarily located in market services areas of Hammond, Baton Rouge, Lafayette, Shreveport-Bossier City, Lake Charles, Alexandria, Dallas-Fort Worth-Arlington, and Waco. First Guaranty Bancshares, Inc. was founded in 1934 and is headquartered in Hammond, Louisiana.
Earnings Per Share
As for profitability, First Guaranty Bancshares has a trailing twelve months EPS of $0.49.
PE Ratio
First Guaranty Bancshares has a trailing twelve months price to earnings ratio of 17.67. Meaning, the purchaser of the share is investing $17.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.37%.
Moving Average
First Guaranty Bancshares’s value is way under its 50-day moving average of $10.40 and way below its 200-day moving average of $10.76.
Revenue Growth
Year-on-year quarterly revenue growth declined by 11.2%, now sitting on 88.8M for the twelve trailing months.
Yearly Top and Bottom Value
First Guaranty Bancshares’s stock is valued at $8.66 at 11:22 EST, way under its 52-week high of $13.91 and above its 52-week low of $8.39.
6. Amazon (AMZN)
11.8% sales growth and 20.31% return on equity
Amazon.com, Inc. engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. In addition, the company offers programs that enable sellers to sell their products in its stores; and programs that allow authors, independent publishers, musicians, filmmakers, Twitch streamers, skill and app developers, and others to publish and sell content. Further, it provides compute, storage, database, analytics, machine learning, and other services, as well as advertising services through programs, such as sponsored ads, display, and video advertising. Additionally, the company offers Amazon Prime, a membership program. The company's products offered through its stores include merchandise and content purchased for resale and products offered by third-party sellers. It serves consumers, sellers, developers, enterprises, content creators, advertisers, and employees. Amazon.com, Inc. was incorporated in 1994 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Amazon has a trailing twelve months EPS of $2.89.
PE Ratio
Amazon has a trailing twelve months price to earnings ratio of 64.4. Meaning, the purchaser of the share is investing $64.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.31%.
Yearly Top and Bottom Value
Amazon’s stock is valued at $186.13 at 11:22 EST, below its 52-week high of $191.70 and way higher than its 52-week low of $118.35.
Revenue Growth
Year-on-year quarterly revenue growth grew by 12.5%, now sitting on 590.74B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 56.9% and 33.7%, respectively.
Volume
Today’s last reported volume for Amazon is 36816600 which is 13.83% below its average volume of 42725600.
Previous days news about Amazon(AMZN)
- According to Zacks on Tuesday, 25 June, "It strives to become the best omnichannel organization, enhancing DKNY and Karl Lagerfeld Paris e-commerce platforms, and partnering with Amazon and Fanatics. "
- According to Zacks on Tuesday, 25 June, "Meanwhile, Amazon is riding on its AI-powered assistant, Amazon Q, allowing conversations, problem-solving, content generation, and insights. ", "BABA’s shares have underperformed Microsoft, Amazon and Alphabet’s gain of 19.5%, 22.1% and 28.4%, respectively, in the year-to-date period."
- According to The Guardian on Wednesday, 26 June, "Meanwhile, the sector is experiencing robust growth, with Amazon having had a 13% increase in revenues from the first quarter of 2023 to the first quarter of 2024."
- According to Zacks on Tuesday, 25 June, "In a bid to bolster its online sales and further compete with fellow omnichannel giant Walmart (WMT Quick QuoteWMT – Free Report) and Amazon (AMZN Quick QuoteAMZN – Free Report) , Target (TGT Quick QuoteTGT – Free Report) announced a partnership with Shopify (SHOP Quick QuoteSHOP – Free Report) on Monday to enhance its e-commerce marketplace."
7. CoreSite Realty Corporation (COR)
9.9% sales growth and 213.15% return on equity
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options — all of which leads to a best-in-class customer experience and lasting relationships.
Earnings Per Share
As for profitability, CoreSite Realty Corporation has a trailing twelve months EPS of $9.15.
PE Ratio
CoreSite Realty Corporation has a trailing twelve months price to earnings ratio of 25.42. Meaning, the purchaser of the share is investing $25.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 213.15%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 9, 2024, the estimated forward annual dividend rate is 2.04 and the estimated forward annual dividend yield is 0.88%.
8. STAAR Surgical Company (STAA)
8.6% sales growth and 4.18% return on equity
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Earnings Per Share
As for profitability, STAAR Surgical Company has a trailing twelve months EPS of $0.31.
PE Ratio
STAAR Surgical Company has a trailing twelve months price to earnings ratio of 131.45. Meaning, the purchaser of the share is investing $131.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.18%.
Volume
Today’s last reported volume for STAAR Surgical Company is 1171200 which is 99.72% above its average volume of 586411.
